Taiwan-Kang BioTech

EirGenix is a leading Taiwanese biotechnology company specializing in the development and manufacture of biologics, including biosimilars and innovative drugs. The company operates a dual business model, functioning as both a product developer with a robust pipeline of oncology-focused biosimilars and a premier Contract Development and Manufacturing Organization (CDMO). Their lead product, EG12014 (a trastuzumab biosimilar), has received regulatory approvals in multiple global markets including the EU and Taiwan. EirGenix leverages advanced mammalian and microbial expression systems to provide end-to-end services from cell line development to commercial-scale production.